Skip to main content
Premium Trial:

Request an Annual Quote

Expression Analysis, Illumina, Agilent Team on Cancer Research Grants

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Expression Analysis today announced a cancer research grant program sponsored by the firm along with Agilent Technologies and Illumina.

Under the program, up to eight American Cancer Society grantees will conduct research into specific cancers and recurring mutations in specific kinases using targeted genome sequencing.

Each of the grantees provide up to 12 human samples — six disease and six control samples — to EA for enrichment using Agilent's SureSelect Human Kinome Kit. EA will then perform the sequencing of the kinome of each sample at no cost using Illumina's Genome Analyzer IIx platform including reagents and flow cells. EA will provide analysis of the sequence data along with final reports and raw sequence data, it said.

"The research community has widely adopted Illumina's sequencing technology and Agilent's SureSelect target enrichment products, so it made perfect sense for our three companies to come together and offer this program," Steve McPhail, president and CEO of EA, said in a statement.

Applications for the grant program are due by March 14. The grant recipients will be chosen by an independent advisory panel and notified by April 10, said EA. More information about the program can be found on EA's website.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.